Transcatheter aortic valve thrombosis: Data from a French multicenter cohort analysis.
TAVI
aortic stenosis
thrombosis
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 08 2021
01 08 2021
Historique:
received:
14
11
2020
accepted:
02
02
2021
pubmed:
23
2
2021
medline:
21
10
2021
entrez:
22
2
2021
Statut:
ppublish
Résumé
To evaluate the effectiveness of anticoagulant therapies in patients with clinical transcatheter heart valve (THV) thrombosis, to describe complications, and to assess their risk profile was the objectives. Little research has been conducted on clinical THV thrombosis. Patients with clinical THV thrombosis were identified based on greater than 50% increased transvalvular gradient on transthoracic echocardiogram confirmed by 4-dimensional computed tomography, transesophageal echocardiogram, or regression with anticoagulant therapy. A cohort free from thrombosis for more than 1,100 days postprocedure was used for comparison. Fifty-four patients with clinical THV thrombosis were identified. Most subjects (98.1%) received anticoagulant therapy which was effective (≥50% reduction in transvalvular gradient or return to postprocedure value) in 96%. The rate of serious hemodynamic or embolic complications in the thrombosis population was 31.5%. A multivariate analysis of subjects with and without thrombosis indicated a significantly increased risk of thrombosis from preexisting thrombocytopenia (odds ratio [OR] 9.96), absence of predilatation (OR = 5.67), renal insufficiency (OR = 4.84), and >10 mmHg mean transvalvular gradient postprocedure (OR = 3.36). No recurrence of thrombosis was identified during on average 685 days follow-up. These data, from one of the largest cohorts with clinical THV thrombosis confirm anticoagulants appear effective. The rate of serious associated complications was high. The findings underline the importance of recognizing risk factors for thrombosis.
Sections du résumé
OBJECTIVES
To evaluate the effectiveness of anticoagulant therapies in patients with clinical transcatheter heart valve (THV) thrombosis, to describe complications, and to assess their risk profile was the objectives.
BACKGROUND
Little research has been conducted on clinical THV thrombosis.
METHODS
Patients with clinical THV thrombosis were identified based on greater than 50% increased transvalvular gradient on transthoracic echocardiogram confirmed by 4-dimensional computed tomography, transesophageal echocardiogram, or regression with anticoagulant therapy. A cohort free from thrombosis for more than 1,100 days postprocedure was used for comparison.
RESULTS
Fifty-four patients with clinical THV thrombosis were identified. Most subjects (98.1%) received anticoagulant therapy which was effective (≥50% reduction in transvalvular gradient or return to postprocedure value) in 96%. The rate of serious hemodynamic or embolic complications in the thrombosis population was 31.5%. A multivariate analysis of subjects with and without thrombosis indicated a significantly increased risk of thrombosis from preexisting thrombocytopenia (odds ratio [OR] 9.96), absence of predilatation (OR = 5.67), renal insufficiency (OR = 4.84), and >10 mmHg mean transvalvular gradient postprocedure (OR = 3.36). No recurrence of thrombosis was identified during on average 685 days follow-up.
CONCLUSIONS
These data, from one of the largest cohorts with clinical THV thrombosis confirm anticoagulants appear effective. The rate of serious associated complications was high. The findings underline the importance of recognizing risk factors for thrombosis.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
352-362Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739-2791.
Waksman R, Corso PJ, Torguson R, et al. Transcatheter aortic valve replacement in low-risk patients: one-year results from the LRT trial. JACC Cardiovasc Interv. 2019;12(10):901-907.
Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015;8(4):1-8.
Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: incidence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 2017;10(7):686-697.
Hafiz AM, Kalra A, Ramadan R, et al. Clinical or symptomatic leaflet thrombosis following transcatheter aortic valve replacement: insights from the US FDA MAUDE database. Struct Heart. 2017;1(5-6):1-9.
Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet Lond Engl. 2017;389(10087):2383-2392.
Vollema EM, Kong WKF, Katsanos S, et al. Transcatheter aortic valve thrombosis: the relation between hypo-attenuated leaflet thickening, abnormal valve haemodynamics, and stroke. Eur Heart J. 2017;38(16):1207-1217.
Makki N, Shreenivas S, Kereiakes D, Lilly S. A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: relationship to cerebrovascular events and valve degeneration. Cardiovasc Revasc Med. 2018;19(7 Pt B):868-873.
Ruile P, Minners J, Breitbart P, et al. Medium-term follow-up of early leaflet thrombosis after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11(12):1164-1171.
Holy EW, Kebernik J, Allali A, El-Mawardy M, Richardt G, Abdel-Wahab M. Comparison of dual antiplatelet therapy versus oral anticoagulation following transcatheter aortic valve replacement: A retrospective single-center registry analysis. Cardiol J. 2017;24(6):649-659.
Kanjanauthai S, Pirelli L, Nalluri N, Kliger CA. Subclinical leaflet thrombosis following transcatheter aortic valve replacement. J Interv Cardiol. 2018;31(5):640-647.
Sondergaard L, Sigitas C, Chopra M, Bieliauskas G, De Backer O. Leaflet thrombosis after TAVI. Eur Heart J. 2017;38(36):2702-2703.
Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68(24):2670-2689.
Basra SS, Gopal A, Hebeler KR, et al. Clinical leaflet thrombosis in transcatheter and surgical bioprosthetic aortic valves by 4DCT. Ann Thorac Surg. 2018;106(6):1716-1725.
Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;38:3382-3390.
Windecker S, Tijssen J, Giustino G, et al. Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO Study. Am Heart J. 2017;184:81-87.
Collet J-P, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. Am Heart J. 2018;200:44-50.
Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. JACC Cardiovasc Imaging. 2016;10:1-11.
Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68(19):2059-2069.
Ruile P, Neumann F-J. Valve thrombosis after TAVI. Eur Heart J. 2017;38(36):2700-2701.
Córdoba-Soriano JG, Puri R, Amat-Santos I, et al. Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Espanola Cardiol Engl Ed. 2015;68(3):198-204.
Ranasinghe MP, Peter K, McFadyen JD. Thromboembolic and bleeding complications in transcatheter aortic valve implantation: insights on mechanisms, prophylaxis and therapy. J Clin Med. 2019;8(2):280.
Vahidkhah K, Barakat M, Abbasi M, et al. Valve thrombosis following transcatheter aortic valve replacement: significance of blood stasis on the leaflets. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg. 2017;51(5):927-935.
Midha PA, Raghav V, Sharma R, et al. The fluid mechanics of transcatheter heart valve leaflet thrombosis in the neosinus. Circulation. 2017;136(17):1598-1609.
Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15(5):408-412.